Online citations, reference lists, and bibliographies.
← Back to Search

Multicenter Laboratory Validation Of The BACTEC MGIT 960 Technique For Testing Susceptibilities Of Mycobacterium Tuberculosis To Classical Second-Line Drugs And Newer Antimicrobials

S. Rüsch-Gerdes, G. Pfyffer, M. Casal, M. Chadwick, S. Siddiqi
Published 2006 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
ABSTRACT The BACTEC MGIT 960 system, a fully automated, nonradiometric, noninvasive system for detection and drug susceptibility testing of mycobacteria, was evaluated for the ability to test susceptibilities to second-line drugs. In this study, which was carried out in three phases (phase I, mostly susceptible strains; phase II, mostly resistant strains; phase III, final testing of the optimal drug concentrations found in phases I and II), we established the critical concentrations for seven drugs to be tested in the BACTEC MGIT 960 system compared to the BACTEC 460TB system. The critical concentrations for the seven drugs used in the MGIT 960 system are as follows: amikacin, 1.0 μg/ml; capreomycin, 2.5 μg/ml; ethionamide, 5.0 μg/ml; protionamide, 2.5 μg/ml; ofloxacin, 2.0 μg/ml; rifabutin, 0.5 μg/ml; linezolid, 1.0 μg/ml. Our results demonstrate that the BACTEC MGIT 960 system is an accurate method for rapid testing of the susceptibilities of Mycobacterium tuberculosis to second-line drugs.
This paper references
Anti-tuberculosis drug resistance in the world : the WHO/IUATLD Global Project on Anti-tuberculosis Drug Resistance Surveillance
Global Tuberculosis Programme (1997)
Use of MGIT 960 for rapid quantitative measurement of the susceptibility of Mycobacterium tuberculosis complex to ciprofloxacin and ethionamide.
T. Huang (2004)
Multidrug-resistant tuberculosis in Russia: clinical characteristics, analysis of second-line drug resistance and development of standardized therapy
Y. Balabanova (2004)
Anti-tuberculosis drug resistance in the world: The WHO/IUATLD Global Project on Anti-Tuberculosis Drug Resistance Surveillance. Geneva: World Health Organization, 1997. 228pp. Price Sw. fr 25/US$22.50 (in developing countries Sw. fir 17.50). (Reference WHO/TB/97.229)
D. Wilkinson (1998)
Evaluation of Moxifloxacin Activity In Vitro Against Mycobacterium tuberculosis, Including Resistant and Multidrug-Resistant Strains
E. Tortoli (2004)
Multicenter Evaluation of the Mycobacteria Growth Indicator Tube for Testing Susceptibility of Mycobacterium tuberculosis to First-Line Drugs
S. Rüsch-Gerdes (1999)
Interlaboratory drug susceptibility testing of Mycobacterium tuberculosis by a radiometric procedure and two conventional methods.
S. Siddiqi (1985)
Multicenter Laboratory Validation of Susceptibility Testing of Mycobacterium tuberculosis against Classical Second-Line and Newer Antimicrobial Drugs by Using the Radiometric BACTEC 460 Technique and the Proportion Method with Solid Media
G. Pfyffer (1999)
The resurgence of tuberculosis: is your laboratory ready?
F. Tenover (1993)
The WHO/IUATLD Global Project on Anti-tuberculosis Drug Resistance Surveillance. WHO/HTM/TB/2004.343. World Heath Organization
BACTEC 460 TB system. Product and procedure manual, revision D
S. H. Siddiqi (1995)
Evaluation of the fully automated Bactec MGIT 960 system for the susceptibility testing of Mycobacterium tuberculosis to first-line drugs: a multicenter study.
F. Kontos (2004)
Resistance of multidrug-resistant strains of Mycobacterium tuberculosis from the Archangel oblast, Russia, to second-line anti-tuberculosis drugs
O. Toungoussova (2005)
Evaluation of the Fully Automated BACTEC MGIT 960 System for Testing Susceptibility of Mycobacterium tuberculosis to Pyrazinamide, Streptomycin, Isoniazid, Rifampin, and Ethambutol and Comparison with the Radiometric BACTEC 460TB Method
C. Scarparo (2004)
BACTEC 460 TB system. Product and procedure manual, revision D. Becton Dickinson Diagnostic Systems
S H Siddiqi (1995)
Kanamycin Susceptibility Testing of Mycobacterium tuberculosis Using Mycobacterium Growth Indicator Tube and a Colorimetric Method
I. Bastian (2001)
Antimicrobial susceptibility testing of Mycobacterium tuberculosis to first-line drugs: comparisons of the MGIT 960 and BACTEC 460 systems.
T. Huang (2002)
Multicenter Evaluation of Fully Automated BACTEC Mycobacteria Growth Indicator Tube 960 System for Susceptibility Testing of Mycobacterium tuberculosis
P. Bémer (2002)
Evaluation of Mycobacteria Growth Indicator Tube for Direct and Indirect Drug Susceptibility Testing ofMycobacterium tuberculosis from Respiratory Specimens in a Siberian Prison Hospital
V. Goloubeva (2001)
Testing of Susceptibility of Mycobacterium tuberculosis to Pyrazinamide with the Nonradiometric BACTEC MGIT 960 System
G. Pfyffer (2002)
Evaluation of Mycobacteria Growth Indicator Tube (MGIT) for drug susceptibility testing of Mycobacterium tuberculosis.
J. Palomino (1999)

This paper is referenced by
, et Complex Mycobacterium tuberculosis Drug Susceptibility Testing of MGIT 960 System for Second-Line Multicenter Evaluation of Bactec
S.-Y. Lin (2009)
Extensively drug-resistant Mycobacterium tuberculosis during a trend of decreasing drug resistance from 2000 through 2006 at a Medical Center in Taiwan.
Chih-Cheng Lai (2008)
The Genus Mycobacteria
Salman H. Siddiqi (2015)
Managing a case of extensively drug-resistant (XDR) pulmonary tuberculosis in Singapore.
C. Phua (2011)
Improving tuberculosis surveillance in Europe is key to controlling the disease.
L. D'Ambrosio (2010)
Prothionamide susceptibility testing of Mycobacterium tuberculosis using the resazurin microtitre assay and the BACTECMGIT 960 system
Y. Tan (2016)
in JapanResistance to Isoniazid Clinical Isolates with tuberculosis Mycobacterium Characteristics of Biological and Molecular
Chiyoji Abe (2010)
Improved early results for patients with extensively drug-resistant tuberculosis and HIV in South Africa.
M. O'Donnell (2009)
Documento de consenso sobre diagnóstico, tratamiento y prevención de la tuberculosis
J. Gonzalez-Martin (2010)
[Current microbiological methods in the investigation of mycobacteria].
E. Richter (2015)
A Novel Inhibitor of Gyrase B Is a Potent Drug Candidate for Treatment of Tuberculosis and Nontuberculosis Mycobacterial Infections
Christopher P Locher (2014)
A simplified mycobacterial growth inhibition assay (MGIA) using direct infection of mouse splenocytes and the MGIT system.
A. Yang (2016)
Autologous mesenchymal stromal cell infusion as adjunct treatment in patients with multidrug and extensively drug-resistant tuberculosis: an open-label phase 1 safety trial.
A. Skrahin (2014)
Evolución de la tuberculosis resistente en la Provincia de Buenos Aires en el período 2006 a 2014
N. Morcillo (2016)
Defining Bedaquiline Susceptibility, Resistance, Cross-Resistance and Associated Genetic Determinants: A Retrospective Cohort Study
N. Ismail (2018)
A genome-wide analysis of multidrug-resistant and extensively drug-resistant strains of Mycobacterium tuberculosis Beijing genotype
Wei Wu (2013)
A Retrospective Study of Pulmonary Tuberculosis (PTB) Prevalence among Patients in Eastern Nigeria Medical Centre Enugu, Nigeria
Mgbe Chinenye Glory (2016)
Direct Drug Susceptibility Testing of Mycobacterium tuberculosis for Rapid Detection of Multidrug Resistance Using the Bactec MGIT 960 System: a Multicenter Study
S. Siddiqi (2011)
Diagnosis of multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis: Current standards and challenges.
G. Migliori (2008)
HIV drug resistance after the use of generic fixed-dose combination stavudine/lamivudine/nevirapine as standard first-line regimen
A. Marcelin (2007)
Drug Susceptibility Testing of Mycobacterium tuberculosis Complex by Use of a High-Throughput, Reproducible, Absolute Concentration Method
Bert van Klingeren (2007)
In Vitro Susceptibility of Mycobacterium tuberculosis to Amikacin, Kanamycin, and Capreomycin
J. Dijkstra (2018)
susceptibility testing methods for first-line and second-line anti-tuberculosis
D. Horne (2012)
The ability of streptomycin-loaded chitosan-coated magnetic nanocomposites to possess antimicrobial and antituberculosis activities
M. E. El Zowalaty (2015)
A four-year nationwide molecular epidemiological study in Estonia: risk factors for tuberculosis transmission.
K. Toit (2014)
Development and evaluation of novel bio-safe filter paper-based kits for sputum microscopy and transport to directly detect Mycobacterium tuberculosis and associated drug resistance
D. Anthwal (2019)
Managing Health Risks of Drug-Resistant Tuberculosis
P. Sampathkumar (2009)
Design, synthesis and biological evaluation of verapamil analogues, reversed isoniazids and hybrid efflux pump inhibitors against Mycobacterium tuberculosis
Malkeet Kumar (2015)
Mycobacteria: Leprosy, a Battle Turned; Tuberculosis, a Battle Raging; Paratuberculosis, a Battle Ignored
R. Greenstein (2009)
polypeptide antibiotics used for the treatment of Mycobacterium tuberculosis 2
P. Juréen (2010)
Epidemiology of antituberculosis drug resistance 2002–07: an updated analysis of the Global Project on Anti-Tuberculosis Drug Resistance Surveillance
A. Wright (2009)
Predictive value of direct nitrate reductase assay and its clinical performance in the detection of multi- and extensively drug-resistant tuberculosis.
B. Imperiale (2014)
See more
Semantic Scholar Logo Some data provided by SemanticScholar